



1-26-07

IFW ✓

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/530,902

Filing Date April 8, 2005

First Named Inventor Graeme Semple

Art Unit Unknown

Examiner Name Unknown

Attorney Docket Number 29.US2.PCT

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Form PTO/SB/08a - 13 pages
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	141 References
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	Return receipt postcard
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Arena Pharmaceuticals, Inc.		
Signature			
Printed name	Lyle W. Spruce		
Date	January 24, 2007	Reg. No.	53,631

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the Date of Deposit shown below, postage prepaid and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature			
Typed or printed name	Tyler Booth	Date	January 24, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Re Application of:

Confirmation No.: 2895

Graeme Semple *et al.*

Serial No.: 10/530,902

Group Art Unit: 1626

Filing Date: April 8, 2005

Examiner: Anderson, Rebecca L

For: **5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES
AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF
METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Express Mail No.: EV862451404US
Date: January 24, 2007

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed. The Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No fee is owed by the Applicants.

Copies of references listed on the attached PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449, are enclosed.

The Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. 50-1441 of any fees associated with this communication.


Respectfully submitted,

Date: 24 January 2007



Lyle W. Spruce
Registration No. 53,631

Arena Pharmaceuticals, Inc.
6166 Nancy Ridge Drive
San Diego, CA 92121
Telephone: (858) 453-7200
Facsimile: (858) 812-3224



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 13

Complete if Known

Application Number	10/530,902
Filing Date	April 8, 2005
First Named Inventor	Graeme Semple
Art Unit	1626
Examiner Name	Anderson, Rebecca L
Attorney Docket Number	29.US2.PCT

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/K.S./ ↓	AA	US- 2005/0143443 A1	06-30-2005	Fang et al.	
	AB	US-2004/0220186 A1	11-04-2004	Bell et al.	
	AC	US-2002/0103215 A1	08-01-2002	Gurram et al.	
	AD	US-6,200,980 B1	03-13-2001	Piazza et al.	
	AE	US- 5,846,990	12-08-1999	Murugesan et al.	
	AF	US-5,464,860	11-07-1995	Lepage et al.	
	AG	US-4,282,361	08-04-1981	Hecht et al.	
	AH	US-4,238,506	12-09-1980	Stach, deceased et al.	
	AI	US-3,980,646	09-14-1976	Brenner et al.	
	AJ	US-3,637,714	01-25-1972	Carlsson et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/K.S./ ↓	AK	WO 2004/085401 A1	10-07-2004	Pfizer		
	AL	WO 2004/078732 A1	09-16-2004	Aventis Pharma S.A.		
	AM	WO 2004/026829 A2	04-01-2004	Boehringer Ingelheim Pharma GMBH & CO. KG		
	AN	WO 03/037899 A1	05-08-2004	Pfizer		
	AO	WO 03/037432 A1	05-08-2003	Pfizer Products Inc.		
	AP	WO 03/035065 A1	05-01-2003	Aventis Pharma Inc.		
	AQ	WO 03/033484 A1	04-24-2003	Bayer Aktiengesellschaft		
	AR	WO 02/062799 A1	08-15-2002	Dr. Reddy's Research Foundation		
	AS	WO 99/54333 A1	10-28-1999	Pfizer Limited		
	AT	WO 98/49166 A1	11-05-1998	Pfizer		
	AU	WO 97/29748 A1	08-21-97	Bristol-Myers Squibb Company		
	AV	WO 02/50091 A1	06-27-2002	Glaxo Group Limited		
	AW	WO 02/10171 A1	02-07-2002	Pfizer		
	AX	WO 01/55136 A1	08-02-2001	Syngenta Limited		
	AY	WO 01/49689 A2	07-12-2001	Warner-Lambert Company		

Examiner
Signature

/Kamal Saeed/

Date
Considered

03/30/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 13

Complete if Known

Application Number	10/530,902
Filing Date	April 8, 2005
First Named Inventor	Graeme Semple
Art Unit	1626
Examiner Name	Anderson, Rebecca L
Attorney Docket Number	29.US2.PCT

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/K.S./	AZ	JP 2004168706 A	06-17-2004	Nissan Chem Ind Ltd.		
↓	BA	WO 01/27113 A2	04-19-2001	Pfizer		
	BB	WO 01/27101 A2	04-19-2001	Pfizer		
	BC	WO 01/02369 A2	01-11-2001	Agouron Pharma Inc.		
	BD	JP 2004217553 A	08-05-2004	Nissan Chem Ind LTD		
	BE	JP 57106665 A	07-02-1982	Showa Denko KK		
↓	BF	JP 02129171 A	05-17-1990	Nissan Chem Ind Ltd		
	BG	EP 1475094 A1	11-10-2004	Ustav Experimentalni Botaniky Akademie ved Ceske Republiky		

Examiner
Signature

/Kamal Saeed/

Date
Considered

03/30/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 13

Complete if Known

Application Number	10/530,902
Filing Date	April 8, 2005
First Named Inventor	Graeme Semple
Art Unit	1626
Examiner Name	Anderson, Rebecca L
Attorney Docket Number	29.US2.PCT

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/K.S./	BH	EP 1348707 A1	10-01-2003	Ustav Experimentalni Botaniky Akademie ved Ceske Republiky		
	BI	EP 1176142 A1	01-30-2002	Pfizer		
	BJ	EP 1092720 B1	01-12-2005	Pfizer		
	BK	EP 0995750 A1	04-26-2000	Pfizer		
	BL	EP 0994115 B1	03-02-2005	Pfizer		
	BM	EP 0562833 A1	03-23-1993	Sankyo Company Limited		
	BN	EP 0463756 B1	06-07-1991	Pfizer		
/K.S./	BO	EP 0459887 A1	05-28-1991	Novapharme		

Examiner
Signature

/Kamal Saeed/

Date
Considered

03/30/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 13

Complete if Known

Application Number	10/530,902
Filing Date	April 8, 2005
First Named Inventor	Graeme Semple
Art Unit	1626
Examiner Name	Anderson, Rebecca L
Attorney Docket Number	29.US2.PCT

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/K.S./	BP	EP 0442430 B1	02-11-1991	Lonza AG		
	BQ	EP 0029364 A1	11-14-1980	Morishita Pharma Co. LTD.		
	BR	EP 0029363 A1	11-14-1980	Morishita Pharma Co. LTD.		
	BS	DE 2604560 A1	08-11-1977	Boehringer Mannheim GmbH		
	BT	DE 2559655 A1	06-02-1977	Fa. Johann A. Wulfig		
	BU	DE 2512886 A1	09-30-1976	Fa. Johann A. Wulfig		
	BV	DE 2454137 A1	05-20-1976	Fa. Johann A. Wulfig		
/K.S./	BW	WO 03/000659	01-03-2003	Nissan Chemical Industries		

Examiner
Signature

/Kamal Saeed/

Date
Considered

03/30/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/530,902
		Filing Date	April 8, 2005
		First Named Inventor	Graeme Semple
		Art Unit	1626
		Examiner Name	Anderson, Rebecca L
		Attorney Docket Number	29.US2.PCT
Sheet	5	of	13

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.S./	BX	HANING et al., "Comparison of Different heterocyclic scaffolds as substrate analog PDE5 inhibitors," <i>Bioorganic & Medicinal Chemistry Letters</i> , (2005), 15(17), 3900-3907	
	BY	WIERZCHOWSKI et al., "Analogues of Formycins A and B: Sythesis and Some Properties of Methyl Derivatives of 7-Amino and 7-Keto Pyrazolo (4,3-d) Pyrimidines," <i>Acta Biochimica Polonica</i> , (1980), 27(1), 35-56	
	BZ	WIPF et al., "Metathesis Reactions of Pyrazolotriazinones Generate Dynamic Combinatorial Libraries," <i>Organic Letters</i> , (2005), 7(20), 4483-4486	
	CA	SIMENEL, "Erratum to 'Synthesis and enantiomeric resolution of ferrocenyl(alkyl)azoles'," <i>Journal of Organometallic Chemistry</i> , (2004), 689(3), 702	
	CB	WISE et al., "Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid," <i>Journal of Biological Chemistry</i> , (2003), 278(11), 9869-9874	
	CC	SIMENEL et al., "Synthesis and enatiomeric resolution of ferrocenyl(alkyl)azoles," <i>Journal of Organometallic Chemistry</i> , (2003), 688(1-2), 138-143	
	CD	FRENCH et al., "Effects of nutritional status and acute variation in substrate supply of cardiac and skeletal-muscle fructose 2,6-bisphosphate concentrations," <i>Biochemical journal</i> , (1988), 250(3), 773-9	
	CE	HOLNESS et al., "Regulation of renal and hepatic pyruvate dehydrogenase complex on carbohydrate re-feeding after starvation," <i>Biochemical journal</i> , (1987), 241(2), 421-5	
	CF	HOLNESS et al., "Effects of Administration of tri-iodothyronine on the response of cardiac and renal pyruvate dehydrogenase complex to starvation for 48 h," <i>Biochemical journal</i> , (1985), 232(1), 255-9	
	CG	SUGDEN et al., " Effects of adrenaline on ketogenesis from long-and medium-chain fatty acids in starved rats," <i>The Biochemical journal</i> , (1982), 204(3), 749-56	
/K.S./	CH	STEINFELDER et al., "In Vitro Effects of Theophylline on Insulin Receptors in Adipocytes: Correlation with the Lipolytic action of the Agent," <i>Biochemical and biophysical research communications</i> , (1982), 104(1), 45-51	

Examiner Signature	/Kamal Saeed/	Date Considered	03/30/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 13

Complete if Known

Application Number	10/530,902
Filing Date	April 8, 2005
First Named Inventor	Graeme Semple
Art Unit	1626
Examiner Name	Anderson, Rebecca L
Attorney Docket Number	29.US2.PCT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.S./	CI	McALLISTER <i>et al.</i> , "The Effect of 5-Methylpyrazole-3-Carboxylate and Nicotinic Acid on Abnormalities of Carbohydrate Metabolism in Alloxan-Diabetic Rat Muscle," <i>Biochemical Pharmacology</i> , (1982), 31(1), 63-8	
	CJ	CREDNER <i>et al.</i> , "Salze der 5-Methylpyrazol-3-carbonsaure mit basisch substituierten Adenin-Derivaten," <i>Arzneimittel-Forschung</i> , (1981), 31(12), 2096-100	
	CK	PODDAR <i>et al.</i> , "Potentiometric Investigation of Complex Equilibria Involving 5(3)- Methylpyrazole-3 (5)-carboxylic Acid with Some Metal Ions in Aqueous Solution," <i>Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical</i> , (1979), 18A(3), 252-4	
	CL	GRIMMETT <i>et al.</i> , "The N-Alkylation and N-Arylation of Unsymmetrical Pyrazoles," <i>Australian Journal of Chemistry</i> , (1979), 32(10), 2203-13	
	CM	LEWIS <i>et al.</i> , "Synthesis of Pyrazolo (4,3-d) Pyrimidines via the Versatile Intermediate Ethyl 3-Methyl-4-nitropyrazole-5-carboxylate," <i>Nucleic Acid Chem.</i> , (1978), 1, 121-8	
	CN	ROSAK <i>et al.</i> , "Chracterization of Lipolytic Responses of Isolated White Adipocytes from Hamsters," <i>Biochimica et Biophysica Acta, General Subjects</i> (1977), 496(2), 458-74	
	CO	BIEROWSKA-CHARYTONOWICZ <i>et al.</i> , "Search for New Aminoguanidine Derivatives with Immunosuppressive and Cytostatic Properties," <i>Archivum Immunologiae et Therapiae Experimentalis</i> , (1976), 24(6), 871-81	
	CP	GIUDICELLI <i>et al.</i> , "Effect of Pyrazole on ACTH Stimulated Lipolysis," <i>Biomedicine</i> , (Paris, France) (1973), 19(2), 48-51	
	CQ	HITTELMAN <i>et al.</i> , " Effects of Antilipolytic Agents and a-Adrenergic Antagonists on Cyclic AMP Metabolism in Hamster White Adipocytes," <i>Biochimica et Biophysica Acta</i> , (1973), 316(3), 403-10	
	CR	MENGEL <i>et al.</i> , "A Comparison of the Antilipolytic Effects of Nicotinic Acid, Methylisoxazole Carboxylic Acid, Methylpyrazole Carboxylic Acid and Insulin in Isolated Fat Cells," <i>Pharmacology</i> , (1972), 8(4-6), 280-90	
/K.S./	CS	GIUDICELLI <i>et al.</i> , " Effect of Pyrazole on Lipolysis," <i>Biochemical Pharmacology</i> , (1972), 21(15), 2095-102	

Examiner Signature	/Kamal Saeed/	Date Considered	03/30/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/530,902
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 8, 2005
		First Named Inventor	Graeme Semple
		Art Unit	1626
		Examiner Name	Anderson, Rebecca L
		Attorney Docket Number	29.US2.PCT
Sheet	7	of	13

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.S./	CT	LOTTI et al., "Derivati Pirazolici Ad Attivita Ipoglicemizzante," <i>Farmaco, Edizione Scientifica</i> , (1972), 27(4), 313-16	
	CU	CARLSON et al., "Potential Hypolipidemic Agents," <i>Acta Pharmaceutica Suecica</i> , (1972), 9(4), 289-304	
	CV	KRANZ et al., "Pyrazolo (1.5-c)pyrimidin - ein neues heterocyclisches System," <i>Chemische Berichte</i> , (1972), 105(2), 388-405	
	CW	BIZZI et al., "Some Aspects of the Effect of Nicotine on Plasma FFA and Tissue Triglycerides," <i>Pharmacology</i> , (1972), 7(4), 216-24	
	CX	GARATTINI et al., "Drugs Affecting Lipolysis," <i>Naunyn-Schmiedeberg's Archiv fuer Pharmakologie</i> , (1971), 269(2-4), 372-9	
	CY	BIZZI et al., "Drugs lowering plasma free fatty acids: Similarities and dissimilarities with nicotinic acid effect," <i>Metab. Eff. Nicotinic Acid Its Deriv., Proc. Workshop</i> , (1971), Meeting Date 1970, 207-20	
	CZ	FROESCH et al., "Effects of nicotinic acid and structurally related drugs on adipose tissue in vitro and on carbohydrate and lipid metabolism of normal and diabetic rats in vivo," <i>Metab. Eff. Nicotinic Acid Its Deriv., Proc. Workshop</i> , (1971), Meeting Date 1970, 773-94	
	DA	BUTCHER et al., "Effects of nicotinic acid on cyclic AMP levels in rat adipose tissue," <i>Metab. Eff. Nicotinic Acid Its Deriv., Proc. Workshop</i> , (1971), Meeting Date 1970, 347-55	
	DB	GARATTINI et al., "Nuove prospettive per il controllo farmacologico dei trigliceridi ematici," <i>Minerva Medica</i> , (1971), 62(72), 3431-2	
	DC	MALAISSIE et al., "Biochemical, Pharmacological, and Physiological Aspects of the Adenylcyclase-Phosphodiesterase System in the Pancreatic β -Cells," <i>Struct. Metab. Pancreatic Islets, Proc. Int. Symp.</i> , (1970), Meeting Date 1969, 435-44	
/K.S./	DD	Tamasi et al., "Changes in serum triglyceride and cholesterol levels independently of free fatty acid after lipolysis inhibitors," <i>Biochemical Pharmacology</i> , (1970), 19(5), 1826-30	

Examiner Signature	/Kamal Saeed/	Date Considered	03/30/2009
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/530,902
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 8, 2005
		First Named Inventor	Graeme Semple
		Art Unit	1626
		Examiner Name	Anderson, Rebecca L
		Attorney Docket Number	29.US2.PCT
Sheet	8	of	13

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.S./	DE	CARMENA et al., "Effect of 5-methylpyrazole-3-carboxylic acid on plasma free fatty acids and blood sugar in geese," <i>Biochemical Pharmacology</i> , (1970), 19(5), 1838-40	
	DF	LUYCKX et al., "Facteurs influencant la secretion de glucagon pancreatique et extrapancreatique," <i>Acta Isotopica</i> , (1970), 10(3-4), 269-84	
	DG	KUPIECKI et al., "Stimulation of lipolysis in adipose tissue in vitro by inhibitors of lipid mobilization," <i>Journal of Lipid Research</i> , (1970), 11(1), 38-41	
	DH	HAVEL et al., "Effects of 5-methylpyrazole-3- carboxylic acid (MPCA) on fat mobilization, ketogenesis and glucose metabolism during exercise in man," <i>Advan. Exp. Med. Biol.</i> , (1969), 4 105-15	
	DI	Tamasi et al., "Szabadzsirsav-csokkento vegyuletek hatasa alloxan-diabeteses patkanyokon," <i>Kiserletes Orvostudomany</i> , (1969), 21(3), 259-63	
	DJ	EASTWOOD et al., "Some effects of 3-chloroisoxazole-5-carboxylic acid on lipid and carbohydrate metabolism," <i>Biochemical Pharmacology</i> , (1969), 18(3), 569-77	
	DK	BIZZI et al., "The hypersensitivity of adipose tissue to norepinephrine and other lipolytic agents during blockade of free fatty acids (FFA) mobilization," <i>Biochemical Pharmacology</i> , (1969), 18(9), 2053-60	
	DL	TAMASI et al., "Comparison of the Antilipemic Effect of Nicotinic Acid (NA) and 3-Methylpyrazole-5-Carboxylic Acid (MPC) in rats," <i>Biochemical Pharmacology</i> , (1968), 17(9), 1789-94	
	DM	BIZZI et al., "Different responses of white and brown adipose tissue to drugs affecting lipolysis," <i>Biochemical Pharmacology</i> , (1968), 17(12), 2407-12	
	DN	KUPIECKI et al., "Effects of 5-Methylpyrazole-3-carboxylic acid (U-19425) and nicotinic acid on lipolysis in vitro and in vivo on cyclic-3',5'-AMP phosphodiesterase," <i>Journal of Pharmacology and Experimental Therapeutics</i> , (1968), 160(1), 166-70	
/K.S./	DO	SICKINGER, "Glucose requirement for prolonged blocking of lipolysis with 3,5-dimethylisoxazole and 5-methylpyrazole-3-carboxylic acid," <i>Klinische Wochenschrift</i> , (1968), 46(10), 563-5	

Examiner Signature	/Kamal Saeed/	Date Considered	03/30/2009
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 13

Complete if Known

Application Number	10/530,902
Filing Date	April 8, 2005
First Named Inventor	Graeme Semple
Art Unit	1626
Examiner Name	Anderson, Rebecca L
Attorney Docket Number	29.US2.PCT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.S./	DP	BIZZI, "Inhibition of fatty acid release by pyrazole derivatives," <i>Progress in Biochemical Pharmacology</i> , (1968), 4 573-7	
	DQ	FANG, "Salicylate hypoglycemic action in alloxan-diabetic rats and structural relationships," <i>Archives Internationales de Pharmacodynamie et de Therapie</i> , (1968), 176(1), 193-208	
	DR	TAMASI et al., "3-(5)-Metil-5-(3)-pirazol-karbonsav (MPK) patkanyok alloxan-diabeteses lipaemiajara gyakorolt hatasa," <i>Acta Pharmaceutica Hungarica</i> , (1968), 38(2-3), 166-70	
	DS	BIZZI et al., "3-Methyl-5-Carboxamidepyrazole, a long lasting inhibitor of lipolysis," <i>Farmaco, Edizione Scientifica</i> , (1967), 22(9), 709-16	
	DT	SMITH et al., "Absorption, Metabolism, and Excretion of 5-Methylpyrazole-3-carboxylic Acid in the Rat, Dog, and Human," <i>Journal of Pharmaceutical Sciences</i> , (1967), 56(9), 1150-7	
	DU	GERRITSEN et al., "Development of Tachyphylaxis to the Antilipolytic, Hypoglycemic Agent, 5-Methylpyrazole-3-carboxylic Acid, U-19425," <i>Proceedings of the Society for Experimental Biology and Medicine</i> , (1967), 126(2), 524-9	
	DV	HOLLOBAUGH et al., "The Effect of a Pyrazole Derivative on Plasma Free Fatty Acids In Man," <i>Metabolism: Clinical and Experimental</i> , (1967), 16(11), 996-1000	
	DW	TAMASI et al., "Effects of 3-Carboxyl-5-Methylpyrazole (CMP) on Serum and Liver Lipids in Rats," <i>Medicina et Pharmacologia Experimentalis</i> , (1967), 16(6), 573-8	
/K.S./	DX	HO et al., "Insulin-Like Action of Quabain I. Effect on Carbohydrate Metabolism," <i>Biochimica et Biophysica Acta</i> , (1967), 144(1), 61-73	

Examiner
Signature

/Kamal Saeed/

Date
Considered

03/30/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10 of 13

Complete if Known

Application Number	10/530,902
Filing Date	April 8, 2005
First Named Inventor	Graeme Semple
Art Unit	1626
Examiner Name	Anderson, Rebecca L
Attorney Docket Number	29.US2.PCT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.S./	DY	SPRIO et al., "Transformazioni nucleari per idrogenolisi. Trasformazione del nucleo isossiazolico in nucleo piridazinico," <i>Annali di Chimica</i> , (Rome, Italy) (1967), 57(7), 846-54	
	DZ	BIZZI et al., "Lowering of plasma triglycerides as a result of a decreased free fatty acid mobilization," <i>Journal of Pharmacy and Pharmacology</i> , (1966), 18(9), 611-14	
	EA	HABRAKEN et al., "Pyrazoles II. Ionisation constants of pyrazolecarboxylic and pyrazoleacetic acids," <i>Recueil des Travaux Chimiques des Pays-Bas</i> , (1966), 85(11), 1194-6	
	EB	Vetulani, "The metabolic activity of some isoxazole and pyrazole derivatives," <i>Dissertationes Pharmaceuticae et Pharmacologicae</i> , (1966), 18(6), 573-84	
	EC	SMITH et al., "5-Methylpyrazole-3-carboxylic Acid. The Potent Hypoglycemic Metabolite of 3,5-Dimethylpyrazole in the Rat," <i>Journal of Medicinal Chemistry</i> , (1965), 8(3), 350-3	
	ED	TABAK et al., "Chromatography of Pyrazole Derivatives on Acetylated Paper," <i>Journal of Chromatography</i> , (1965), 17(3), 520-7	
	EE	FROESCH et al., "Insulin Inhibition of Spontaneous Adipose Tissue Lipolysis and Effects upon Fructose and Glucose Metabolism," <i>Molecular Pharmacology</i> , (1965), 1(3), 280-96	
	EF	SMITH et al., "Metabolism of 3,5-dimethylpyrazole-C ¹⁴ in the rat," <i>Journal of Pharmacology and Experimental Therapeutics</i> , (1965), 150(2), 316-21	
	EH	HAMLIN et al., "Relationship between in vitro dissolution rates and solubilities of numerous compounds representative of various chemical species," <i>Journal of Pharmaceutical Sciences</i> , (1965), 54(11), 1651-3	
	EI	GERRITSEN et al., "The effect of 5-Methylpyrazole-3-Carboxylic Acid on Carbohydrate and Free Fatty Acid Metabolism," <i>Journal of Pharmacology and Experimental Therapeutics</i> , (1965), 150(3), 491-8	
/K.S./	EJ	MARSHTUPA et al., "The solubility of propylene in aromatic hydrocarbons," <i>Khim. Prom.</i> , (1965), 41(8), 585-7	

Examiner Signature	03/30/2009	Date Considered	03/30/2009
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/530,902
			Filing Date	April 8, 2005
			First Named Inventor	Graeme Semple
			Art Unit	1626
			Examiner Name	Anderson, Rebecca L
			Attorney Docket Number	29.US2. PCT
Sheet	11	of	13	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.S./	EK	RINGEL et al., "Darstellung and Aminolyse des 1,1,1-Trichloracetylacetons," <i>Journal fuer Praktische Chemie</i> , (Leipzig) (1964), 26(5-6), 333-9	
	EL	GRANDBERG, "Pyrazoles XXXIV. Ultraviolet Spectra of Pyrazole Systems," <i>Zhurnal Obshchei Khimii</i> , (1963), 33 519-25	
	EM	TABAK et al., "Investigation of Pyrazoles XXV. Paper Chromatography of Pyrazolecarboxylic Acids," <i>Zhurnal Obshchei Khimii</i> , (1962), 32 1562-4	
	EN	HOPFF et al., "Über Decarboxylierung und Dissoziation heterocyclischer Dicarbonsauren," <i>Helvetica Chimica Acta</i> , (1961), 44 1058-63	
	EO	D'AGOSTINO et al., "Reducing activity in vitro of certain antibiotic and chemotherapeutic drugs," <i>Aggiorn. Pediat.</i> , (1961), 12(10), 477-84	
	EP	TERENT'EV et al., "Pyrazoles IX. New Method of Synthesizing Pyrazolecarboxylic Acids," <i>Zhurnal Obshchei Khimii</i> , (1960), 30 2925-31	
	EQ	DAL MONTE et al., "Ricerche sugli eterociclici: spettri di assorbimento U.V. e proprietà cromoforiche," <i>Gazzetta Chimica Italiana</i> . (1956), 86 797-848	
	ER	DAL MONTE et al., "Ricerche nella serie dei pirazoli: Spettri U.V. di alcuni metal-, carbossi- e fenil-pirazoli," <i>Bollettino Scientifico della Facolta di Chimica Industriale di Bologna</i> , (1954), 12 147-9	
	ES	AINSWORTH et al., "Reactions of Hydrazines with γ-pyrones," <i>Journal of the American Chemical Society</i> , (1954), 76, 3172-4	
	ET	LLYOD et al., "The Dissociation Constants of Cupric Salts of Some Monocarboxylic Acids," <i>Journal of the Chemical Society</i> , (1951), 1786-9	
/K.S./	EU	PINO, "Le Costanti di dissociazione di alcuni derivati della serie del pirazolo e dell' isossazolo," <i>Annali di Chimica</i> , (Rome, Italy) (1950), 40 575-92	

Examiner Signature	/Kamal Saeed/	Date Considered	03/30/2009
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/530,902
				Filing Date	April 8, 2005
				First Named Inventor	Graeme Semple
				Art Unit	1626
				Examiner Name	Anderson, Rebecca L
				Attorney Docket Number	29. US2.PCT
Sheet	12	of	13		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
↓ /K.S./	EV	HENRY et al., "Aromatic Isocyanates as Reagents for the Identification of Some Heterocyclic Compounds," <i>Journal of the American Chemical Society</i> , (1949), 71, 2297-2300	
	EW	HUTTEL et al., "Uber die Loslichkeit der Pyrazol-und Triazolaldehyde in Alkalien," <i>Ann.</i> , (1947), 558, 34-47	
	EX	MUSANTE et al., "La degradazione di Curtius applicata ad alcuni acidi pirazolcarbonici," <i>Gazzetta Chimica Italiana</i> , (1947), 77, 182-98	
	EY	MUSANTE, "Su alcuni acidi pirazolcarbonici e loro derivati," <i>Gazzetta Chimica Italiana</i> , (1945), 75, 121-36	
	EZ	DEWAR et al., "Sulphanilamides of Some Aminopyrazoles, and a Note on the Application of <i>p</i> -Phthalimidobenzenesulphonyl Chloride to the Synthesis of Sulphanilamides," <i>Journal of the Chemical Society</i> , (1945), 114-16	
	FA	LANGLEY et al., "Solubility of the Flavianates of Certain Organic Bases in Water, Ethanol, and <i>n</i> -Butanol at 3 and 30°," <i>Journal of the American Chemical Society</i> , (1942), 64, 2507-8	
	FB	CUSMANO, "Transformation di acidi γ-issosiazolcarbonici in derivati del pirazolo," <i>Gazzetta Chimica Italiana</i> , (1940), 70, 235-40	
	FC	AUWERS et al., "Uber Acyl-pyrazole," <i>Journal fuer Praktische Chemie</i> , (Leipzig) (1930), 126 146-76	
	FD	SAGI et al., "Studies on the Metabolism of Azolecarboxylic Acids Closely Related to the Fusaric Acid (5-Butylpyridine-2-carboxylic Acid)," <i>Yakugaku Zasshi</i> , (1988), 108(4), 350-4	
	FE	YAMANAKA et al., "Sytheses of Heteroaromatic Carboxylic Acids Closely Related to Fusaric Acid," <i>Chemical & Pharmaceutical Bulletin</i> , (1983), 31(12), 4549-53	
/K.S./	FF	KESKIN, "Semikarbazid'in α,γ-diketoasitler ve bunlarin etil esterleri uzerine etkimesi," <i>Rev. faculte Sci. Univ. Istanbul</i> ,(1944), 9A, 81-9	

Examiner Signature	/Kamal Saeed/	Date Considered	03/30/2009
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/530,902
		Filing Date	April 8, 2005
		First Named Inventor	Graeme Semple
		Art Unit	1626
		Examiner Name	Anderson, Rebecca L
Sheet 13 of 13	Attorney Docket Number	29.US2.PCT	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.S./	FG	HUO et al., "Methyl 4-bromo-1,3-dimethylpyrazole-5-carboxylate," <i>Acta Crystallographica, Section E: Structure Reports Online</i> , (2003), E59(12), o2013-o2014	
	FH	EHLERT et al., "Polynuclear pyrazolate complexes of copper. Crystal and molecular structures of...", <i>Canadian Journal of Chemistry</i> , (1992), 70(8), 2161-73	
	FI	ROJAHN et al., "Beitrag zur Kenntnis der Rosenmundschen Aldehydsynthese im heterocyclischen system," <i>Arch. Pharm.</i> , (1926), 264, 337-47	
	FJ	MORGAN et al., "CLII.- Substitution in the Pyrazole Series. Halogen Derivatives of 3 : 5-Dimethylpyrazole," <i>Journal of the Chemical Society, Transactions</i> , (1923), 123 1308-18	
/K.S./	FK	BANKS et al., "Fluorocarbon Derivatives of Nitrogen. Part 8. Reactions Between Heteroaromatic N-Imines (N-Iminopyridinium and N-Iminoquinolinium Ylide) and Perfluoropropene, 2H-Pentafluoropropene, Perfluorobut-2-ene, Perfluoro-(2-methylpent-2-ene), Perfluorobut-2-yne, and Perfluoropyridine: Synthesis of Fluorinated 3-Azaindolizines (Pyrazolo[1,5-a]-pyridines)," <i>Journal of the Chemical Society, Perkin Transactions 1</i> , (1982), (7), 1593-600	

Examiner Signature	/Kamal Saeed/	Date Considered	03/30/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.